Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
0 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cognition Therapeutics, Inc.’s names, not what it holds today.
Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
19
1 of them in 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
'14'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name1 counted
Cognition Therapeutics, Inc. its own name
named as the applicant on its applications, in US
19 published
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jun 5, 2025 | 2025/0177351 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Pharmaceuticals | Cognition Therapeutics, Inc. |
| Dec 12, 2024 | 2024/0409509 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | Organic fine chemistry | Cognition Therapeutics, Inc. |
| May 23, 2024 | 2024/0165077 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGIC DISEASES | Pharmaceuticals | Cognition Therapeutics, Inc. |
| May 9, 2024 | 2024/0150288 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Organic fine chemistry | Cognition Therapeutics, Inc. · patent 12,466,795 granted from it |
| Jan 11, 2024 | 2024/0009168 | COMPOSITIONS FOR TREATING DRY AGE-RELATED MACULAR DEGENERATION (AMD) | Pharmaceuticals | Cognition Therapeutics, Inc. |
| Mar 30, 2023 | 2023/0098944 | METHOD OF DECREASING AMYLOID BETA MONOMER LEVELS IN PATIENTS WITH COGNITIVE DECLINE | Pharmaceuticals | Cognition Therapeutics, Inc. |
| Nov 10, 2022 | 2022/0356153 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | Organic fine chemistry | Cognition Therapeutics, Inc. · patent 11,981,636 granted from it |
| Jan 14, 2021 | 2021/0009517 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Organic fine chemistry | Cognition Therapeutics, Inc. · patent 11,691,947 granted from it |
| Oct 29, 2020 | 2020/0338045 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Analysis of biological materials | Cognition Therapeutics, Inc. |
| Sep 24, 2020 | 2020/0299234 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | Organic fine chemistry | Cognition Therapeutics, Inc. · patent 11,214,540 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Organic fine chemistry 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.